Welcome to our dedicated page for Revolution Medicines news (Ticker: RVMD), a resource for investors and traders seeking the latest updates and insights on Revolution Medicines stock.
Revolution Medicines, Inc. (RVMD) is a clinical-stage precision oncology company dedicated to discovering and developing innovative targeted therapies that address the unmet needs of cancer patients. The company leverages its proprietary product engine to target frontier oncology pathways, with a strong focus on the RAS and mTOR signaling pathways, which are crucial for cancer growth and survival. Revolution Medicines’ approach draws inspiration from nature and evolution, harnessing insights from natural products to guide the discovery and development of small molecules that modulate key cancer targets.
The company’s research and development pipeline features several promising candidates, including RMC-4630, a SHP2 inhibitor, and a portfolio of RAS(ON) inhibitors such as RMC-6236, RMC-6291, and RMC-9805. These novel therapies aim to inhibit the active form of RAS proteins, which are common drivers in numerous cancer types. Revolution Medicines is also advancing the SOS1 and 4EBP1/mTORC1 programs, which hold significant potential in combination treatment strategies.
Recent achievements highlight the company’s progress in clinical development. Notably, the RMC-6236 Phase 1/1b trial demonstrated promising clinical activity and a favorable safety profile in patients with advanced solid tumors harboring KRAS mutations. The trial results showed an objective response rate of 38% in non-small cell lung cancer (NSCLC) and 20% in pancreatic ductal adenocarcinoma (PDAC), with disease control rates of 85% and 87%, respectively.
In October 2023, Revolution Medicines announced a pivotal milestone with the merger with EQRx, Inc., enhancing its financial position and enabling further investment in its clinical programs. The merger is expected to add approximately $1.1 billion in net cash proceeds, supporting the advancement of their RAS(ON) and RAS Companion Inhibitors. Dr. Sandra Horning, a renowned oncologist and former Genentech executive, joined the board of directors, bringing invaluable experience to the company.
Revolution Medicines continues to engage the scientific community and stakeholders through presentations at major conferences and investor webcasts. The company remains committed to advancing its robust pipeline of oncology therapies, aiming to revolutionize the treatment landscape for RAS-addicted cancers and improve outcomes for cancer patients worldwide.
Revolution Medicines (Nasdaq: RVMD) announced that CEO Mark A. Goldsmith will present at the 39th Annual J.P. Morgan Healthcare Conference from January 11-14, 2021. During the presentation, scheduled for January 12 at 5:20 p.m. Eastern, Dr. Goldsmith will discuss the advancement of two first-in-class RAS(ON) Inhibitor programs into IND-enabling development. He will also provide updates on three RAS Companion Inhibitors: RMC-4630, RMC-5552, and the newly introduced RMC-5845. The presentation will be available via webcast on the company's website.
Revolution Medicines (RVMD) provided an update on its RMC-4630 programs for RAS-addicted cancers, announcing selected Phase 2 doses for both monotherapy and combination therapies. Financial results for Q3 2020 show revenue of $12.7 million, up from $12.5 million in Q3 2019. However, R&D expenses rose to $34.9 million, leading to a net loss of $27.2 million, compared to a loss of $12.8 million in the previous year. The company has positioned itself as a leader in RAS-targeted therapies and has extended its clinical collaborations to enhance its drug development pipeline.
Revolution Medicines (RVMD) recently presented interim data from its Phase 1b/2 trial of RMC-4630 combined with cobimetinib at the EORTC-NCI-AACR Symposium. The dual intermittent dosing strategy showed tolerable adverse effects and exceeded target plasma exposures, indicating potential clinical activity in KRAS-mutated colorectal cancers. Additionally, a new collaboration with AstraZeneca aims to explore RMC-4630's combination with a KRAS-targeting drug. Preliminary results suggest anti-tumor activity, with tumor volume reduction in three of seven patients receiving the highest dose.
Revolution Medicines, Inc. (NASDAQ: RVMD) announced that interim data from its Phase 1b/2 trial, RMC-4630-02, will be presented at the EORTC-NCI-AACR 32nd Symposium on October 24-25, 2020. This trial evaluates the safety and efficacy of RMC-4630 in combination with cobimetinib for patients with relapsed/refractory solid tumors. The company aims to explore drug combinations as a strategy to overcome resistance mechanisms in RAS-addicted cancers. The presentation will focus on dosing regimens and pharmacokinetic findings.
Revolution Medicines (Nasdaq: RVMD) presented groundbreaking data on its KRASG12D(ON) inhibitors, showcasing their ability to induce tumor regressions in a preclinical human pancreatic cancer model. This marks the first public demonstration of anti-tumor activity for these inhibitors, emphasizing their potential in treating cancers associated with the KRASG12D mutation, which is significant given the lack of approved therapies targeting this mutation. The KRASG12D(ON) program is entering lead optimization after showing effective dose-dependent anti-tumor results.
Revolution Medicines, Inc. (Nasdaq: RVMD) announced that CEO Mark A. Goldsmith will present at the H.C. Wainwright 22nd Annual Global Investment Conference from September 14-16, 2020. His presentation is scheduled for September 14 at 11:00 a.m. Eastern Time. A live webcast will be accessible through the company's website, with a replay available post-conference. Revolution Medicines focuses on precision oncology, developing targeted therapies for RAS-addicted cancers, including RMC-4630 and RMC-5552, aimed at inhibiting critical cancer signaling pathways.
Revolution Medicines (Nasdaq: RVMD) will participate in the 2nd Annual RAS-Targeted Drug Development Conference from September 14-16, 2020. Key presentations include:
- Title: Approaches to Inhibiting RAS Driven Tumors Beyond KRAS G12C
Presenter: Steve Kelsey, M.D.
Date: September 16, 2020, 9:00 a.m. Eastern - Title: Empowering Combination Strategies to Target RAS Mutant Cancers
Participant: Jan Smith, Ph.D.
Date: September 16, 2020, 4:30 p.m. Eastern - Workshop: Navigating the Future Potential of Combination Strategies
Co-Leader: Jan Smith, Ph.D.
Date: September 14, 2020, 11:30 a.m. Eastern
Revolution Medicines (Nasdaq: RVMD) announced the closing of a public offering of 6,900,000 shares at $26.00 each, generating gross proceeds of $179.4 million before deductions. The offering included 900,000 additional shares purchased by underwriters. The funds are expected to support the company’s focus on developing targeted cancer therapies, specifically those targeting RAS and mTOR pathways. J.P. Morgan, Cowen, SVB Leerink, and Guggenheim Securities managed the offering.
Revolution Medicines has announced a public offering of 6,000,000 shares of common stock at a price of $26.00 per share, aiming to raise approximately $156 million before expenses. The offering includes an option for underwriters to purchase up to 900,000 additional shares. The offering is set to close on July 13, 2020, subject to standard closing conditions. Notable financial institutions involved include J.P. Morgan, Cowen, SVB Leerink, and Guggenheim Securities.
Revolution Medicines, Inc. (Nasdaq: RVMD) has launched an underwritten public offering of 5,500,000 shares of common stock. The company plans to grant underwriters a 30-day option to purchase an additional 825,000 shares. J.P. Morgan, Cowen, SVB Leerink, and Guggenheim Securities are serving as joint book-running managers for the offering. A registration statement has been filed with the SEC, but it is not yet effective. This press release does not constitute an offer to sell or a solicitation to buy securities.
FAQ
What is the current stock price of Revolution Medicines (RVMD)?
What is the market cap of Revolution Medicines (RVMD)?
What does Revolution Medicines, Inc. specialize in?
What are some of the key products in Revolution Medicines’ pipeline?
What recent achievements has Revolution Medicines reported?
What is the significance of the RMC-6236 Phase 1/1b trial?
How does the merger with EQRx benefit Revolution Medicines?
Who recently joined the board of Revolution Medicines?
What are RAS(ON) inhibitors?
How does Revolution Medicines generate insights for its drug discovery?
What are some of the ongoing trials at Revolution Medicines?
How can investors stay updated on Revolution Medicines’ developments?
